TREA

97187427 - BIO-COURIER

Follow

Information

  • Trademark
  • 97187427
  • Serial Number
    97187427
  • Registration Number
    7430532
  • Filing Date
    December 23, 2021
    3 years ago
  • Registration Date
    June 25, 2024
    6 months ago
  • Transaction Date
    June 25, 2024
    6 months ago
  • Status Date
    June 25, 2024
    6 months ago
  • Location Date
    June 24, 2024
    6 months ago
  • Status Code
    700
  • Current Location
    FILE REPOSITORY (FRANCONIA)
    Employee Name
    SORIANO, JASMINE
  • Attorney Docket Number
    008814.00012
    Attorney Name
    Evi Christou
  • Owners
Information
Mark Drawing Code
4
Mark Identification
BIO-COURIER
Case File Statements
  • GS0051: Nanoparticle substances and nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical purposes; silicon nanoparticle substances and silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical purposes; porous silicon nanoparticle substances and porous silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical purposes; lipid nanoparticle substances and lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical purposes; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical purposes; silicon-stabilised hybrid lipid nanoparticles for medical, veterinary and nanoparticle substances and nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments; silicon nanoparticle substances and silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments; porous silicon nanoparticle substances and porous silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments; lipid nanoparticle substances and lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments; nanoparticle substances and nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical treatment purposes; silicon nanoparticle substances and silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical treatment purposes; porous silicon nanoparticle substances and porous silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical treatment purposes; lipid nanoparticle substances and lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical treatment purposes; silicon-lipid nanoparticle substances and lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical treatment purposes; silicon-stabilised hybrid lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes; silicon-stabilised lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes; stabilised lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes; materials for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticles for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticles for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; materials for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticles for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticles for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; materials for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticles for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticles for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; materials for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticles for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticles for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticle materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticle materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticle materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticle materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; all of the foregoing excluding use in the agricultural industry
  • GS0011: Nanoparticle substances and nanoparticles for use in industry, science and research; Silicon, namely, silicon for use in industry, science and research in the nature of biochemical catalysts; Silicon, namely, silicon nanoparticle materials for use in industry, science and research; Silicon, namely, porous silicon nanoparticle materials for use in industry, science and research; lipid nanoparticles for use in industry, science and research; Silicon, namely, silicon-lipid nanoparticles for use in industry, science and research; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for use in industry, science and research; Silicon, namely, silicon-stabilised lipid nanoparticles for use in industry, science and research; stabilised lipid nanoparticles for use in industry, science and research; materials being silicon for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; Silicon, namely, silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; Silicon, namely, porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; Silicon, namely, silicon lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; Silicon, namely, silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; materials being silicon for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; Silicon, namely, silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; Silicon, namely, porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; Silicon, namely, silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; Silicon, namely, silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; Silicon, namely, silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; Silicon, namely, porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; Silicon, namely, silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; Silicon, namely, silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; Silicon, namely, silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; Silicon, namely, porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; Silicon, namely, silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; Silicon, namely, silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; materials for stabilising of chemical, biochemical and biological substances; nanoparticle materials for stabilising of chemical, biochemical and biological substances; Silicon, namely, silicon nanoparticle materials for stabilising of chemical, biochemical and biological substances; Silicon, namely, porous silicon nanoparticle materials for stabilising of chemical, biochemical and biological substances; lipid nanoparticle materials for stabilising of chemical, biochemical and biological substances; Silicon, namely, silicon-lipid nanoparticle materials for stabilising of chemical, biochemical and biological substances; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for stabilising of chemical, biochemical and biological substances; Silicon, namely, silicon-stabilised lipid nanoparticles for stabilising of chemical, biochemical and biological substances; stabilised lipid nanoparticles for stabilising of chemical, biochemical and biological substances; materials for stabilising nucleic acids; nanoparticle materials for stabilising nucleic acids; Silicon, namely, silicon nanoparticle materials for stabilising nucleic acids; Silicon, namely, porous silicon nanoparticle materials for stabilising nucleic acids; lipid nanoparticle materials for stabilising nucleic acids; Silicon, namely, silicon-lipid nanoparticle materials for stabilising nucleic acids; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acids; Silicon, namely, silicon-stabilised lipid nanoparticles for stabilising nucleic acids; stabilised lipid nanoparticles for stabilising nucleic acids; materials for stabilising nucleic acid-lipid complexes; nanoparticle materials for stabilising nucleic acid-lipid complexes; Silicon, namely, silicon nanoparticle materials for stabilising nucleic acid-lipid complexes; Silicon, namely, porous silicon nanoparticle materials for stabilising of nucleic acid-lipid complexes; lipid nanoparticle materials for stabilising nucleic acid-lipid complexes; Silicon, namely, silicon-lipid nanoparticle materials for stabilising nucleic acid-lipid complexes; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acid-lipid complexes; Silicon, namely, silicon-stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes; stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes; all of the foregoing other than for medical or veterinary purposes and excluding use in the agricultural industry
Case File Event Statements
  • 12/27/2021 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 12/30/2021 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 9/27/2022 - 2 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 10/27/2022 - 2 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 10/27/2022 - 2 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 10/27/2022 - 2 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 4/20/2023 - a year ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 9/5/2023 - a year ago
    8 - ASSIGNED TO LIE Type: ALIE
  • 9/5/2023 - a year ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 9/5/2023 - a year ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 10/16/2023 - a year ago
    13 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 10/16/2023 - a year ago
    11 - FINAL REFUSAL WRITTEN Type: CNFR
  • 10/16/2023 - a year ago
    12 - FINAL REFUSAL E-MAILED Type: GNFR
  • 1/15/2024 - 11 months ago
    14 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR
  • 1/15/2024 - 11 months ago
    15 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG
  • 4/11/2024 - 8 months ago
    18 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/11/2024 - 8 months ago
    17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/11/2024 - 8 months ago
    16 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 6/25/2024 - 6 months ago
    20 - REGISTERED-SUPPLEMENTAL REGISTER Type: R.SR
  • 6/25/2024 - 6 months ago
    21 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCS
  • 5/22/2024 - 7 months ago
    19 - APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER Type: CNTA